Trade Vir Biotechnology VIR

Sell
 Buy

VirBiotechnology live chart

5m 15m 30m 1h 4h 1d 1w

Instrument Fundamentals

Weekly Search
Weekly
Daily
Date Close Change Change (%) Open High Low

VirBiotechnology news

Latest news

Show more
2025 Oct 31, 00:00

LME to Permanently Restrict Large Positions Amidst Low Inventory

2025 Oct 22, 10:04

The Future of Payments: Fragmentation, Digital Assets, and AI

2025 Oct 22, 07:21

Daily Market Review and Trend Analysis: October 22

2025 Oct 22, 07:20

Crypto Cities: Challenges and Opportunities for a Decentralized Future

2025 Oct 22, 07:20

OpenAI's Atlas Browser: A Glimpse into the Future of AI Agents on the Web

2025 Oct 22, 00:00

Precious Metals Retreat Amid Easing Trade Tensions and Rate Cut Expectations

2025 Oct 22, 00:00

Australian Gold Rush: Record Prices Spark Queues and Investment Debate

Finance Magnates Africa Summit 2023
Shaun Edwards 2023 Apr 10, 02:10

Join markets.com and Bryan Habana at Finance Magnates Africa Summit 2023!

Info

Spread

0.10

Spread (%)

0.8857 %

Leverage

1:10

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Markets closed

Tuesday

13:31 - 19:59

Wednesday

13:31-19:59

Thursday

13:31-19:59

Friday

13:31-19:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

1813995008

Shares Outstanding

169215958

Earnings Date (Next)

0000-00-00

Div Yield

Ex-Dividend Date

Forward annual dividend rate

0

Forward annual dividend yield

0

EPS

-1.71

Learn more about this instrument

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Related Instruments

Asset
Sell
Buy
Change (%)

Trade Now

Trade Now

Trade Now

Trade Now
View all instruments

latest_education_articles

Show more
Trustpilot